These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 28888756

  • 1. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression.
    Ohata K, Kamijo-Ikemori A, Sugaya T, Hibi C, Nakamura T, Murase T, Oikawa T, Hoshino S, Katayama K, Asano J, Kimura K, Shibagaki Y.
    Eur J Pharmacol; 2017 Nov 15; 815():88-97. PubMed ID: 28888756
    [Abstract] [Full Text] [Related]

  • 2. Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.
    Kamijo-Ikemori A, Sugaya T, Hibi C, Nakamura T, Murase T, Oikawa T, Hoshino S, Hisamichi M, Hirata K, Kimura K, Shibagaki Y.
    Am J Physiol Renal Physiol; 2016 Jun 01; 310(11):F1366-76. PubMed ID: 27029427
    [Abstract] [Full Text] [Related]

  • 3. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
    Nakamura T, Murase T, Nampei M, Morimoto N, Ashizawa N, Iwanaga T, Sakamoto R.
    Eur J Pharmacol; 2016 Jun 05; 780():224-31. PubMed ID: 27038523
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Xanthine crystals induced by topiroxostat, a xanthine oxidoreductase inhibitor, in rats, cause transitional cell tumors.
    Shimo T, Moto M, Ashizawa N, Matsumoto K, Iwanaga T, Saito K.
    Arch Toxicol; 2014 Apr 05; 88(4):1035-42. PubMed ID: 24448833
    [Abstract] [Full Text] [Related]

  • 10. Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor.
    Taniguchi T, Ashizawa N, Matsumoto K, Iwanaga T, Saitoh K.
    J Pharm Pharmacol; 2016 Jan 05; 68(1):76-83. PubMed ID: 26589240
    [Abstract] [Full Text] [Related]

  • 11. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
    Terawaki H, Hoshi H, Kazama JJ.
    Clin Exp Nephrol; 2017 Apr 05; 21(2):356-357. PubMed ID: 28247173
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis.
    Peleli M, Zollbrecht C, Montenegro MF, Hezel M, Zhong J, Persson EG, Holmdahl R, Weitzberg E, Lundberg JO, Carlström M.
    Free Radic Biol Med; 2016 Oct 05; 99():472-484. PubMed ID: 27609225
    [Abstract] [Full Text] [Related]

  • 14. Renal liver-type fatty acid binding protein attenuates angiotensin II-induced renal injury.
    Ichikawa D, Kamijo-Ikemori A, Sugaya T, Yasuda T, Hoshino S, Igarashi-Migitaka J, Hirata K, Kimura K.
    Hypertension; 2012 Oct 05; 60(4):973-80. PubMed ID: 22926951
    [Abstract] [Full Text] [Related]

  • 15. Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats.
    Kawamorita Y, Shiraishi T, Tamura Y, Kumagai T, Shibata S, Fujigaki Y, Hosoyamada M, Nakagawa T, Uchida S.
    Physiol Rep; 2017 Aug 05; 5(15):. PubMed ID: 28774949
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency.
    Brown NJ, Bradford J, Wang Z, Lea W, Ma L, Ma J, Vaughan DE, Fogo AB.
    Kidney Int; 2007 Jul 05; 72(1):72-81. PubMed ID: 17429342
    [Abstract] [Full Text] [Related]

  • 18. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
    Horino T, Hatakeyama Y, Ichii O, Matsumoto T, Shimamura Y, Inoue K, Terada Y, Okuhara Y.
    Clin Exp Nephrol; 2018 Apr 05; 22(2):337-345. PubMed ID: 28752287
    [Abstract] [Full Text] [Related]

  • 19. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
    Wada T, Hosoya T, Honda D, Sakamoto R, Narita K, Sasaki T, Okui D, Kimura K.
    Clin Exp Nephrol; 2018 Aug 05; 22(4):860-870. PubMed ID: 29372470
    [Abstract] [Full Text] [Related]

  • 20. Xanthine Oxidoreductase Inhibitors Suppress the Onset of Exercise-Induced AKI in High HPRT Activity Urat1-Uox Double Knockout Mice.
    Hosoya T, Uchida S, Shibata S, Tomioka NH, Matsumoto K, Hosoyamada M.
    J Am Soc Nephrol; 2022 Feb 05; 33(2):326-341. PubMed ID: 34799437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.